ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why SIRP-alpha-Fc Fusion Protein HCB101 is on this study

  • The record lists it as a treatment, written “HCB101”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 3:40 AM UTC
  • The role rule said “Background”; the reading replaced it.
  • So SIRP-alpha-Fc Fusion Protein HCB101's page lists this study under “Testing it”.
20 links0 made here, not in the record39 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT06771622Safety and Efficacy ofHCB101 in Combination WithMultiple Agents in PatientsWith Advanced Solid TumorsFBD Biologics LimitedPhase 1/Phase 2 · active not rRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSSolid CancerNo longer in the registry's filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSSIRP-alpha-Fc Fusion Protei…Entry “HCB101”, read by our name rule›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerOxaliplatinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundRamucirumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundBevacizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCetuximabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLeucovorinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundFluorouracilEntry “5-FU”, read by our name rule›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundToripalimabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAlbumin-Bound PaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPembrolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCarboplatinEntry “Carboplatin (AUC 5)”, read by …›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEtoposideIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAtezolizumabIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerTrastuzumab deruxtecanIntervention entry›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partner

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2SIRP-alpha-Fc Fusion Protein HCB101Claude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · partnerCurrent
Nov 2PertuzumabClaude Opus 5.5Background · partnerCurrent
Nov 2OxaliplatinClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2RamucirumabClaude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2BevacizumabClaude Opus 5.5BackgroundCurrent
Nov 2CetuximabClaude Opus 5.5BackgroundCurrent
Nov 2IrinotecanClaude Opus 5.5BackgroundCurrent
Nov 2LeucovorinClaude Opus 5.5BackgroundCurrent
Nov 2FluorouracilClaude Opus 5.5BackgroundCurrent
Nov 2ToripalimabClaude Opus 5.5BackgroundCurrent
Nov 2Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 2CarboplatinClaude Opus 5.5BackgroundCurrent
Nov 2EtoposideClaude Opus 5.5BackgroundCurrent
Nov 2AtezolizumabClaude Opus 5.5Background · partnerCurrent
Nov 2Trastuzumab deruxtecanClaude Opus 5.5Background · partnerCurrent
Nov 14Solid CancerRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18SIRP-alpha-Fc Fusion Protein HCB101Rule based · role ruleBackgroundOverridden
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18PertuzumabRule based · role ruleBackgroundAgrees
Nov 18OxaliplatinRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18RamucirumabRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18BevacizumabRule based · role ruleBackgroundAgrees
Nov 18CetuximabRule based · role ruleBackgroundAgrees
Nov 18IrinotecanRule based · role ruleBackgroundAgrees
Nov 18LeucovorinRule based · role ruleBackgroundAgrees
Nov 18FluorouracilRule based · role ruleBackgroundAgrees
Nov 18ToripalimabRule based · role ruleBackgroundAgrees
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18CarboplatinRule based · role ruleBackgroundAgrees
Nov 18EtoposideRule based · role ruleBackgroundAgrees
Nov 18AtezolizumabRule based · role ruleBackgroundAgrees
Nov 18Trastuzumab deruxtecanRule based · role ruleBackgroundAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.